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Abstract
Regenerative medicine studies using autologous bone marrow mononuclear cells (BM-MNCs) have shown
improved clinical outcomes that correlate to in vitro BM-MNC invasive capacity. The current Boyden-chamber assay
for testing invasive capacity is labor-intensive, provides only a single time point, and takes 36 hours to collect data
and results, which is not practical from a clinical cell delivery perspective. To develop a rapid, sensitive and
reproducible invasion assay, we employed Electric Cell-substrate Impedance Sensing (ECIS) technology.
Chemokine-directed BM-MNC cell invasion across a Matrigel-coated Transwell filter was measurable within
minutes using the ECIS system we developed. This ECIS-Transwell chamber system provides a rapid and sensitive
test of stem and progenitor cell invasive capacity for evaluation of stem cell functionality to provide timely
clinical data for selection of patients likely to realize clinical benefit in regenerative medicine treatments. This
device could also supply robust unambiguous, reproducible and cost effective data as a potency assay for cell
product release and regulatory strategies.
Introduction
Measurement of a stem, progenitor, or stromal cell prepa-
ration’s potency or functionality is important to the
characterization of a potential cell therapy product [1].
Ideally, the assessment of a cell product’s potency is based
on a relevant cell function for the desired clinical outcome
[2]. While valuable, assessments of cell phenotype (i.e.,
surface marker expression), viability, and colony growth
are not considered adequate functionality tests for cells
being studied in clinical applications because they do
not reliably predict clinical responses to cell treatments
[1–4]. For regenerative therapies, the therapeutic cell’s
ability to invade injured tissue in response to a chemo-
tactic gradient is considered to be a critical cell func-
tion for the desired clinical outcome [5–8]. To assess
the potential in vivo invasive capacity of a stem-cell
preparation, an in vitro Transwell invasion assay is typ-
ically performed [9–12]. This assay is based upon the
Boyden chamber, which is separated into upper and lower
chambers by a Matrigel matrix-coated porous filter. The
progenitor or stem cells are added to the top chamber and
a chemoattractant agent is added to the bottom chamber
to induce the cells to invade the Matrigel matrix and
migrate through the porous filter to the bottom chamber.
Eighteen to 24 hours later, the number of cells that have
migrated to the underside of the filter or to the floor of
the bottom chamber is quantified by 4′,6-diamidino-2-
phenylindole (DAPI) staining and then counting the
migrated cells’ nuclei [13]. Transwell assay measurement
of bone marrow mononuclear cell (BM-MNC) invasion in
response to stromal cell-derived factor-1 (SDF-1) was
found to be the only in vitro assessment of BM-MNC
preparations that demonstrated a positive correlation to
the clinical outcome of patients treated with BM-
MNCs for heart repair [14, 15]. The SDF-1 Transwell
invasion assay has also been used for testing the invasive
function of other progenitor cell types such as mesenchy-
mal stromal cells (MSCs) [16–18], endothelial progenitor
cells (EPCs) [19–21], and peripheral blood mononuclear
cells (PB-MNCs) [22–24]. While the standard Transwell
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invasion assay has been found to provide clinically im-
portant data on the functional capacity of stem cell
preparations, limitations to the assay include the time
required for measurable migration of cells, labor-
intensive methods required for quantifying the invasive
cells, investigator inter-assay variability, and measure-
ment of migration (a dynamic process) at only a single
(for example, 18–24 hour) time point [25, 26]. For
autologous bone marrow cell therapy, the largest limi-
tation of present cell function assays is that the results
are not available until about 36 hours after the bone
marrow harvest. Since many clinical applications of
autologous bone marrow stem and progenitor cells in-
volve the cells being administered within a few hours of
the bone marrow harvest, it is not then possible to
identify, prospectively, stem cell preparations with poor
functional capacity. For clinical trials designed to deter-
mine the therapeutic potential of a stem cell therapy,
the inclusion of suboptimal cell preparations reduces
the statistical power of the study, obscuring the poten-
tial benefit of the therapy under assessment. Import-
antly, whether as part of a clinical trial or an accepted
treatment protocol, administration of suboptimal cell
preparations can result in patients being treated without a
high likelihood of clinical benefit. This assay also ad-
dresses the need of the Food and Drug Administration
(FDA) and other regulatory organizations for a reliable,
low-cost, rapid assay of cell functionality as a cell potency
test.
Many patients have preexisting clinical conditions
that can impact the functionality of their stem cells. For
example, it is well documented that diabetes can impair
BM-MNC functionality [27–30], but whether such an
existing clinical condition has impacted a patient’s stem
cell functionality to a degree that the patient should
not undergo cell administration is presently difficult to
assess in the hours between autologous stem cell har-
vest and administration. Another circumstance where a
quick and sensitive cell migration assay for measuring
cell functionality would be helpful is in the testing of
stem cells from patient blood or bone marrow before and
after radiotherapy or chemotherapy treatment [31–33].
Some of the undesired side effects from radiation therapy,
chemotherapy, or treatment with bone marrow suppres-
sive drugs are the reduction of peripheral blood stem cell
viability and function [34]. In this regard, a cell potency in-
vasion assay to measure the functionality of peripheral
blood cells would be important in assessing the potential
toxic effects of radiation therapy and chemotherapy.
With the continued development of cell biosensor de-
tection methods, traditional methods, such as the Boy-
den chamber for studying cell invasion, are being
updated with newer analytical tools [35–38]. A cell inva-
sion assay involves the cells first degrading an extracellular
matrix barrier or cell monolayer, followed by the movement
of the cells through the porous filter in response to the che-
mokine gradient [25, 39, 40]. In these studies, electric cell-
substrate impedance sensing (ECIS), previously used to de-
tect the invasion of cells through a cell monolayer grown
directly on an electrode array [41] or on a porous filter [42],
is used to detect the invasion of cells through an extracellu-
lar matrix barrier on a porous filter.
The goal of this study was to adapt the standard
Transwell assay to a stem cell invasion assay using ECIS
technology for use as a rapid, reliable stem cell func-
tionality or potency assay. The objective of the study was
to automate the measurement of cell invasion using resist-
ance and impedance measurements that could detect SDF-
1-directed cell invasion in minutes rather than 36 hours.
We also sought to demonstrate early proof-of-principle re-
sults showing that sublethal, deleterious effects of cell func-
tionality could be detected as a consequence of exposure
of stem cells to common doses of radiation cancer therapy
regimens. Here, we show that by translating the standard
Transwell assay to an assay using ECIS technology, one
can measure within minutes BM-MNC invasion in re-
sponse to SDF-1. The BM-MNC invasion is dependent on
specific signaling by SDF-1; BM-MNCs pretreated with
SDF-1 or AMD3100 (a SDF-1 receptor blocker) do not in-
vade the Matrigel matrix. We also demonstrate that ECIS
measurement of SDF-1 stimulated PB-MNC invasion and
that radiation-exposure damage of the PB-MNCs reduces
their invasion. The results from our experiments demon-
strate that the ECIS Transwell device and chamber pro-
vides a rapid, sensitive, and reproducible test of BM-MNC
and PB-MNC invasion capacity, making it a potential diag-
nostic tool for testing stem cell functionality in regenerative
medicine studies.
Methods
Bone-marrow harvest and purification
pt?>All bone marrow samples were collected from 12-
month-old male domestic Sinclair miniswine (Sinclair
Bio-resources, Columbia, MO, USA). All animal hand-
ling and care procedures were performed strictly in
accordance with the 2004 National Research Council
“Guide for the Care and Use of Laboratory Animals” fol-
lowing protocol approval by the Institutional Animal
Care and Use Committee (IACUC) of the Legacy Clin-
ical Research and Technology Center, Legacy Health
System, Portland, OR, USA. Under local anesthesia,
40 ml porcine bone marrow was aspirated from either
the donor’s tibia or sternum into a syringe containing
5 ml heparin (1000 USP units/ml). The bone marrow
was transferred into a 150 ml transfer bag (Baxter, Deer-
field, IL, USA) containing 8 ml citrate–phosphate dextran
(Sigma, St. Louis, MO, USA), and the bone marrow trans-
fer bag was connected through a 40 μm Pall blood
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transfusion filter (Fisher Sci., 300 Industry Drive, Pitts-
burgh, PA, USA) to a SEPAX cartridge kit (#CS-900; Bio-
safe America, Houston, TX, USA). This kit contained a
wash-buffer bag that was filled with Hanks’ balanced salt
solution containing cations (HBSS; Invitrogen, 3175 Staley
Road, Grand Island, NY, USA) and a density gradient so-
lution/waste bag that was filled with 100 ml Ficoll-Paque
Premium-1077 (GE Health Care, Pittsburg, PA, USA). A
150 ml transfer bag (Baxter Health Care, One Baxter
Parkway, Deerfield, IL, USA) was connected to receive the
purified BM-MNCs. The completed kit was then placed
into a SEPAX-2 (Biosafe America) automated cell-
processing device to process the bone marrow [29]. The
final purified BM-MNC product was collected in HBSS
and the BM-MNCs were counted with a Beckman Z2-
Coulter Counter (Beckman Coulter, Brea, CA, USA).
Isolation of porcine PB-MNCs
Porcine peripheral blood was collected from the fem-
oral artery of domestic Yorkshire swine and diluted 1:2
with HBSS (#14025-092; Gibco/Invitrogen, 3175 Staley
Road, Grand Island, NY, USA). PB-MNCs were isolated
by density gradient centrifugation. Specifically, a 4 ml
aliquot of diluted blood was layered on top of 3 ml
Ficoll-Paque Premium, density 1.077 (#17-5442-02; GE
Healthcare, Pittsburgh, PA, USA) in a 15 ml centrifuge
tube, and the tubes were centrifuged (400 × g, 40 mi-
nutes, room temperature, no brake). The recovered PB-
MNCs were washed twice with HBSS (300 × g, 10 mi-
nutes, room temperature). After washing, the cells were
resuspended in X-VIVO 15 media (#04-744Q; Lonza,
Walkersville, MD USA), and an aliquot was taken for cell
counting and viability assessment.
Jurkat cell culture
Human Jurkat T-cell line (JJK subclone) cells were
grown in RPMI-1640 media (#15-10.1186/s13287-015-
0182-2040-CV; Corning CellGro, Mediatech, Inc., Ma-
nassas, VA) supplemented with penicillin–streptomycin
(#15140-122; Gibco/Invitrogen, 3175 Staley Road, Grand
Island, NY, USA), l-glutamine (#25030-081; Gibco/Invi-
trogen, 3175 Staley Road, Grand Island, NY, USA), and
10 % fetal bovine serum (Premium FBS, #14-501 F;
Lonza, Walkersville, MD USA). The Jurkat cells were
cultured in a 37°C carbon dioxide (CO2) incubator, and
were split 1:5 when the cells reached a concentration of
1 × 106 cells/ml. The cells for this study were split no
more than 25 times relative to the original stock of cells.
Radiation of PB-MNCs
To show that our stem cell functionality assay could rap-
idly detect nonlethal deleterious changes in cell function
in previously functioning cells, we exposed the cells to a
radiation dose comparable with commonly prescribed
doses for cancer radiotherapy in humans. The PB-MNCs
in X-VIVO 15 media received 0 Gy or 2.15 Gy of X-ray ir-
radiation at room temperature (1.365 Gy/minute, RS2000
Biological Research Irradiator; Rad Source, Suwanee, GA,
USA). The dose of 2.15 Gy was chosen for the swine cells
since it is comparable with a moderate radiation exposure
of human cells [43].
After irradiation of the PB-MNCS the cells were not
washed, because it has been shown previously with
other cell types that there is no difference in the rate of
apoptosis if the cells are kept in the original irradiated
medium or switched to fresh medium [44]. Also, an
additional wash (centrifugation) step has the potential
to produce additional damage to cells [45], which
would complicate the interpretation of the effects of
radiation alone on the invasion assay results. Both the
irradiated cells and the nonirradiated cells were then cul-
tured in hydrophobic dishes (Nunc Hydrocell, #174912;
ThermoFisher Sci., Waltham, MA, USA) for 24 hours
in X-VIVO 15 media (37 °C, 5 % CO2), after which they
were centrifuged (300 × g, 1 minute, room temperature)
and resuspended in fresh X-VIVO 15 media. The final
cell concentration was adjusted to 1.2 × 106 cells/300 μl
X-VIVO 15 media for the ECIS Transwell invasion
assay.
ECIS Transwell invasion assay
The invasive function of the BM-MNCs, PB-MNCs,
and Jurkat cells in response to a chemokine gradient
was quantified using a commercial ECIS-Zθ system
(Applied BioPhysics, Inc., Troy, NY, USA) connected to
a Transwell array device (ECIS Trans-Filter Adapter;
Applied BioPhysics, Inc.) (Fig. 1) employing a Matrigel-
coated, 8 μm pore, Transwell filter insert (#354480; BD
Fig. 1 Schematic of the ECIS Transwell array device developed and
used for this study. Commercially available Matrigel-coated Transwell
filters fit into the ECIS Transwell array device, which has individual
reference electrodes embedded in the bottom chamber with
independent sensing electrodes placed above the filters
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Biocoat, Fisher, Pittsburg, PA, USA). To minimize any
inter-assay variation, the Transwell array station and
transfilter adaptor were always prewarmed in a humidi-
fied 5 % CO2 incubator for 2 hours, and then warm
(37 °C) media were always used for resuspending the
cells and chemokines. BM-MNCs, Jurkat cells, or PB-
MNCs (1.2 × 106 cells) were brought to a final volume of
300 μl in X-VIVO 15 media and added to the chamber
above the Matrigel-coated Transwell filter insert. For ex-
periments measuring BM-MNC or Jurkat cell invasion,
SDF-1 (#350-NS; R&D Systems, Minneapolis, MN, USA)
in X-VIVO 15 media (100 ng/ml in 625 μl medium) was
added to the chamber below the Matrigel-coated Trans-
well filter. For the PB-MNC ECIS Transwell studies, SDF-
1 (100 ng/ml) and MIP-1 (100ng/ml; PeproTech, Rocky
Hill, NJ, USA) were used in combination because both
chemoattractants have been shown to be involved in PB-
MNC migration [46, 47]. After the addition of the re-
spective cells and chemokines, the ECIS Transwell de-
vice was placed in an incubator (37 °C, 5 % CO2) for
2 hours, during which time the impedance changes were
recorded.
The migratory action of SDF-1 is the result of SDF-1
binding to the receptor C-X-C chemokine receptor type
4 (CXCR4) [48, 49]. For some control experiments, the
BM-MNCs were pretreated for 30 minutes with 5 μg/ml
AMD3100 (an inhibitor of the SDF-1 receptor, CXCR4
[50, 51]), and then the cells were added to the top of the
ECIS Transwell chamber and 100 ng/ml SDF-1 was
added to the bottom chamber. In other control experi-
ments, to distinguish between a directed chemotaxis ver-
sus a random chemokinesis response, 100 ng/ml SDF-1
was added with the cells to the top of the ECIS Transwell
chamber and medium alone was added to the bottom
chamber.
ECIS data analysis and statistics
Initial data analysis was performed using ECIS Software
(version 1.2.123; Applied BioPhysics, Inc.). The actual
filter resistance of each test or control well was calcu-
lated by subtracting from each the resistance of a blank
Transwell filter without cells:
actual filter resistance
¼ test well resistanceð Þ – blank filter resistanceð Þ
The actual filter resistance values for replicate wells
were then averaged and plotted as the mean ± standard
error of the mean (SEM) over the 2-hour time course.
Additional analysis was done by transferring the data to
an Excel 2011 spreadsheet (Microsoft, Redmond, WA,
USA) where the absolute relative change in resistance was
calculated at specific times by subtracting the initial
baseline resistance at time zero from its respective actual
filter resistance value:
absolute relative resistance
¼ actual filter resistanceð Þ – baseline resistanceð Þ
The absolute relative resistance was plotted as the mean
± SEM [52]. Significant differences between the ECIS re-
sistance changes of control and chemokine-treated groups
were calculated using a one-way analysis of variance test
and a probability of p <0.05. Graphs were plotted as the
mean ± SEM using SigmaPlot-11 (Systat Software, Inc.,
Chicago, IL, USA). The use of “n” in our study was equal
to the number of individual animals used for the isolation
of the BM-MNCs and PB-MNCs, which was 4 and 2, re-
spectively. For the Jurkat cells, “n” in our study was equal
to the number of separate individual cell platings.
Results
ECIS measurement of chemotactic cell invasion
Since the invasion of human cells from the Jurkat T-
cell line to SDF-1 has been well characterized in stand-
ard Boyden chamber migration assays [26, 53–55], we
used Jurkat T cells to characterize our ECIS invasion
assay. The assays employed an ECIS Transwell device
developed for this study (Fig. 1). The ECIS Transwell
device holds a standard Matrigel-coated Transwell filter,
typically used for invasion assays. Jurkat T cells were
placed in the Transwell top chambers and the chemokine
SDF-1 was added to the bottom chambers. We found a
significant increase in SDF-1-stimulated Jurkat cell inva-
sion of the Matrigel matrix measured by ECIS as increased
resistance (Fig. 2). Jurkat cells placed in the top half of a
chamber without SDF-1 in the bottom half of the chamber
produced only a slight increase in filter resistance that sta-
bilized within 45–60 minutes and did not increase further
over the remaining 2-hour time course (Fig. 2a). The ECIS
system continuously measures the resistance across the
Transwell membrane over time. When the absolute rela-
tive changes in filter resistance from Jurkat invasion in
chambers with and without SDF-1 in the bottom half of
the chamber (test and control chambers, respectively)
were plotted over time, we found that the change in filter
resistance for chambers with SDF-1 versus without SDF-1
became significantly different (p <0.05) within 10 minutes
after starting the assay (i.e., after the addition of SDF-1),
and that the difference increased over the 2-hour observa-
tion period (Fig. 2b).
For traditional Boyden chamber assays, cell migration or
invasion across porous filters can be classified as either a
random motion event in the absence of a chemokine gra-
dient (i.e., chemokinesis) or directed migration in response
to a chemokine gradient (i.e., chemotaxis) [26, 56–58]. For
our assay we wanted to determine whether the SDF-1
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change in filter resistance correlated to a directed chemo-
tactic response. SDF-1 was added along with the Jurkat T
cells to the top chamber and not to the bottom chamber
of Transwells. As would be anticipated for a chemotactic
response, there was no measurable increase in Transwell
filter resistance when SDF-1 was added to the same cham-
ber as the Jurkat T cells (i.e., the upper chamber) (Fig. 3),
which is in contrast to the increased resistance measured
when Jurkat T cells are added to the top chamber and
SDF-1 is added to the bottom chamber of the Transwell
(Fig. 2).
SDF-1 stimulates cell invasion and migration as a result
of it binding to the receptor CXCR4 [48, 49]. For some
control experiments, the BM-MNCs were pretreated for
30 minutes with 5 μg/ml AMD3100 (an inhibitor of the
SDF-1 receptor, CXCR4 [50, 51]), and then the cells were
Fig. 2 ECIS measurement of increased Transwell filter resistance resulting from SDF-1 chemokine-dependent Jurkat T-cell invasion of Matrigel-coated
Transwell filters. Jurkat T cells were placed in the upper chambers of Matrigel-coated Transwells with or without addition of 100 ng/ml SDF-1 to the
lower chambers. a Transwell filter resistance is measured continuously over time by ECIS. Combined resistance tracings of six separate experiments are
shown for Transwells with and without the addition of SDF-1 to the lower chamber, demonstrating the increased resistance in Transwells where the
Jurkat T cells invade the Matrigel in response to SDF-1. Arrow: time point of SDF-1 addition to test lower chambers. Mean ± SEM. b The absolute
change in ECIS Transwell filter resistance, relative to the resistance measured at the zero time point, increases over 2 hours due to Jurkat T-cell Matrigel
invasion in response to SDF-1. Each bar represents the mean ± SEM of six separate experiments (n = 6) performed in duplicate. *p <0.05. SDF-1 stromal
cell derived factor-1
Fig. 3 Increased ECIS Transwell filter resistance is due to chemotaxis, not chemokinesis, and is specific to the chemokine (SDF-1). In these experiments,
Jurkat T-cells were used without pretreatment or were pretreated with either 100 ng/ml SDF-1 or AMD3100 (an inhibitor of the SDF-1 receptor). Resistance
was measured in wells with Jurkat T cells (without or with pretreatment) added to top chambers with and without SDF-1 in the bottom chambers. Arrow:
time point of SDF-1 addition to test lower chambers. Each tracing represents the mean ± SEM of two separate experiments (n= 2) performed in duplicate.
SDF-1 stromal cell derived factor-1
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added to the top of the ECIS Transwell chamber and
100 ng/ml SDF-1 were added to the bottom chamber. In a
conventional Boyden chamber assay, AMD3100 treatment
of the test cells inhibits their SDF-1-directed chemotaxis
[54, 56, 59–61]. As shown in Fig. 3, there was no increase
in filter resistance when the AMD3100 pretreated cells
were added to the top chamber of the Transwell with
SDF-1 in the lower chamber, demonstrating the SDF-1
specificity of the ECIS-measured chemotactic invasive
Jurkat T-cell function. These results demonstrate that the
primary mechanism for the ECIS-measured change in the
Transwell filter resistance is an SDF-1-specific chemotac-
tic cell invasion response.
ECIS measurement of mononuclear cell invasive function
Using the ECIS Transwell invasion assay characterized
above, we examined whether it would provide a rapid
measurement of the invasive function of BM-MNCs in re-
sponse to the chemokine SDF-1. We found that within
10 minutes there was measurable unambiguous increased
resistance across Matrigel-coated Transwell filters when
SDF-1 was added to the lower Transwell chamber (Fig. 4a).
The resistance continued to rise over the first 90 minutes
and then plateaued for the remainder of the 2-hour assay
(Fig. 4a). Without the chemotactic signal of SDF-1 added
to the bottom chamber, BM-MNCs added to the upper
chamber did not increase the resistance across the
Matrigel-coated Transwell filter at any time point within
the 2-hour assay (Fig. 4a). Increased resistance was con-
firmed to be associated with BM-MNC invasion of the
Matrigel coating the filter by microscopic observation of
BM-MNCs within the Matrigel and the presence of cells
adherent to the underside of the filter and on the floor of
the bottom chamber (results not shown). When the
absolute relative changes in resistance were plotted over
time, the change in filter resistance for Transwells with
SDF-1 versus without SDF-1 in the lower chambers was
significantly different (p <0.05) as rapidly as 5 minutes
after initiating the ECIS measurements, and the difference
increased over the 2-hour study period (Fig. 4b).
We also examined whether the ECIS Transwell inva-
sion assay could measure the nonlethal toxic effects of
radiation. Porcine PB-MNCs were exposed to X-ray
radiation at 0 Gy and 2.15 Gy. The dose of 2.15 Gy was
chosen for the porcine PB-MNCs since it is comparable
with that found as a moderate therapeutic radiation
exposure for cancer therapies [43]. The control and irradi-
ated cells were then cultured for 24 hours, the viable cells
were recovered from culture, and their invasive capacity
in response to combined SDF-1 and MIP-1 was measured
by ECIS. Control (nonirradiated) PB-MNCs invaded the
Matrigel in response to SDF-1 plus MIP-1, increasing the
measured resistance across the Matrigel-coated Transwell
membrane (Fig. 5a). In contrast, there was no significant
increase in resistance when the PB-MNCs had been
exposed to 2.15 Gy of X-rays (Fig. 5a). When the relative
absolute changes in resistance were plotted over time, the
change in filter resistance for Transwells with chemo-
kines (SDF-1 plus MIP-1) versus without chemokines
in the lower chambers was significantly different (p <0.05)
as rapidly as 30 minutes after initiating the ECIS measure-
ments, and the difference increased over the 2-hour study
period (Fig. 5b). The differences in the invasive function
of the control (0 Gy) versus test (2.15 Gy) PB-MNC popu-
lations was not due to the viability of the cells added to
the ECIS Transwell Matrigel-invasion assays, as the
viability of both PB-MNC populations was ≥95 %
(0 Gy: 98.1 % ± 0.31 %; 2.15 Gy: 98.3 ± 0.35 %; n = 2).
Fig. 4 Bone marrow mononuclear cell invasive function can be measured by ECIS. a ECIS Transwell filter resistance increases over 2 hours as a
result of porcine BM-MNC invasion of Matrigel in response to SDF-1. Without the addition of SDF-1 to the lower chamber, the porcine BM-MNCs
(added to the upper chamber) did not invade the Matrigel, resulting in no increase in the resistance (lower tracing). Arrow: time point of SDF-1
addition to test lower chambers. Each tracing represents the mean ± SEM of results from four separate experiments. b The absolute change in
ECIS Transwell filter resistance, relative to the resistance measured at the zero time point, increases over 2 hours due to porcine BM-MNC Matrigel
invasion in response to SDF-1. Each bar represents the mean ± SEM of separate BM-MNC isolations from four different animals (n = 4). *p <0.05.
SDF-1 stromal cell derived factor-1
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Discussion
It is now being recognized that for stem and progeni-
tor cells to be an effective regenerative therapy,
characterization of their cell-surface markers and colony-
forming unit (CFU) capacity might not be sufficient
release criteria for establishing their cellular biological
activity. Recent retrospective studies of results from clin-
ical trials in cardiac regenerative cell therapy have shown
that a measurement of therapeutic cell functional capacity
is essential [62]. One of the principle assays for assessing
progenitor or stem cell functionality is the in vitro cell in-
vasion assay [1, 63, 64]. The standard in vitro cell invasion
assay typically has a single endpoint measurement, mea-
sured 18–24 hours after the initiation of the assay. Since
most autologous stem and progenitor cell therapy regi-
mens administer cells within a few hours of their harvest,
prospective evaluation of stem cell potency prior to cell
treatments using this assay has not been possible. Retro-
spective evaluations using these assays have accurately
identified patients who have a favorable benefit from cell
therapy as well as patients who do not realize a clinical
benefit. Thus, many patients have been treated with
cells that were unlikely to provide clinical benefit, ex-
posing patients to risks of the procedure with little
benefit and reducing the statistical power of the study.
To develop a rapid assessment of cell invasive capacity,
this study investigated a new approach for the dynamic
monitoring of cell invasion using ECIS technology and a
modified Transwell chamber device. Using human Jurkat
T cells, a cell line well characterized for its transmigra-
tion capacity in standard invasion assays, we found that
there was a significant invasive response, as reflected by
a change in ECIS Transwell resistance, that could easily
be detected within 10 minutes after starting the assay
(i.e., after the addition of SDF-1 to the lower Transwell
chamber). This ECIS Transwell chemotactic response to
SDF-1 was found to be specific to the chemokine in that
the addition of AMD3100, a blocker of the SDF-1 recep-
tor, abolished any change in the SDF-1-induced change
in Transwell resistance. We also demonstrated that both
bone marrow and PB-MNC invasion could be measured
using this ECIS Transwell assay. Importantly, measure-
ment by ECIS allows cell invasion to be quantified
within minutes, making it possible to include a cell prep-
aration’s invasion and migration functional capacity as
part of the release criteria for cell administration. The
ECIS Transwell assay can thus be used to quantify rap-
idly the invasive and migratory function of cells, facilitat-
ing timely acquisition of cell function data.
The ECIS Transwell invasion assay described provides
quantitative results rapidly and continuously over time
for the invasion and migration of cells through a
Matrigel-coated Transwell filter. Table 1 compares the
ECIS Transwell invasion assay with the traditional Boy-
den chamber Transwell assay. The traditional Boyden
chamber Transwell assay has a single endpoint for each
well, typically 18–24 hours following the addition of the
cells to the well. For example, in a traditional Boyden
Fig. 5 ECIS measurement of decreased PB-MNC invasive function resulting from radiation exposure. PB-MNCs were irradiated (2.15 Gy) or not
irradiated, cultured for 24 hours, and then added to the upper chambers of ECIS Transwells, with 100 ng/ml SDF-1 and 100 ng/ml MIP-1 chemokines
added to the appropriate bottom chambers at time zero (arrow). a Resistance measurement tracings over time demonstrating the loss of invasive
function by irradiated PB-MNCs. Mean ± SEM. b The absolute change in ECIS Transwell filter resistance, relative to the resistance measured at the zero
time point, is decreased by irradiation of PB-MNCs. Each bar represents the mean ± SEM of separate PB-MNC isolations from two different
animals (n = 2). *p <0.05. ECIS electric cell-substrate impedance sensing
Table 1 Comparison of ECIS invasion assay versus standard
invasion assay
ECIS method Standard Boyden method




Total run time: 36 hours
(24 hours to perform assay,
post-assay fixing of filters,
histological staining, and
imaging or CyQuant assay)
Data acquisition Continuous One time point (24 hours)
ECIS electric cell-substrate impedance sensing
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chamber assay there was a significant delay within the
first 90 minutes after the addition of SDF-1 before any
significant Jurkat transmigration could be detected [26].
In contrast, with ECIS we measured significant BM-MNC
and Jurkat invasion and transmigration by 5 and 10 mi-
nutes, respectively, after the addition of SDF-1.
ECIS is a real-time, label-free, impedance-based method
used to study the activities of cells in tissue culture [35].
The ECIS technique is highly sensitive to the changes in
the electrical resistance of the porous Transwell filter,
making this method a valuable tool for quickly assessing
changes in cell transmigration. The rapid changes ob-
served in the ECIS signal are probably due to the
chemokine-stimulated cells at the top of the filter mov-
ing to and reaching the 8 μm diameter pores and
attempting to transmigrate through the pores. As more
stimulated cells on the filter surface crawl to the pore
sites and attempt to transmigrate, the effective pore diam-
eters are reduced, which increases the resistance across
the filter. This phenomenon is described by Coulter’s re-
sistive pulse measurement theory [65].
We also found for both BM-MNCs and Jurkat T cells
that the SDF-1-induced changes in ECIS filter resistance
began to plateau between 1 and 2 hours after the initi-
ation of the experiment. A partial explanation for this
observation is that the chemotactic gradient starts to
become dissipated within a few hours, resulting in the
pores becoming occluded due to slow or nontransmi-
grating cells. Additional experiments are now underway
to further clarify the relationship between changes in the
ECIS signal and the corresponding physical transmigra-
tion cell morphology (CR, personal communication).
Cell migration can continue to occur in the absence of a
concentration gradient due to the random walk of cells or
chemokinesis [26]. In fact, when the SDF-1 chemokine is
placed with cells in the top portion of the Transwell filter,
a random migratory cell movement walk can occur with
some of the cells going through the filter to the bottom
chamber [26, 57, 66]. In our studies, however, no change
in filter resistance was detected when SDF-1 was added
along with the cells to the top chamber over the 2-hour
period. This indicates that when SDF-1 is added to the
bottom chamber, cell chemotaxis, and not chemokinesis,
is responsible for the increased resistance measurement of
the cell invasion response. This is similar to the data from
previous studies using the traditional Transwell assay with
Jurkat T cells where only chemotaxis, and not chemokin-
esis, was found to be involved in SDF-1-stimulated Jurkat
cell migration [56, 67].
While the speed by which ECIS can be used to quantify
cell invasion and migration makes it particularly desirable
for assessing the functional capacity of therapeutic cell
products, it may also be applicable for monitoring the
function of a patient’s cells in relation to a disease process
or therapy. For example, radiotherapy is an important
therapeutic treatment for a variety of cancers, but as the
radiotherapy dosage increases it has major side effects
including decreased function of the patient’s PB-MNCs
[34, 68, 69]. This radiation effect on cells can be critical
since many tissue-committed stem/progenitor cells circu-
late in the peripheral blood and migrate to tissue-specific
niches for healing and repair [70]. The optimal maximal
radiotherapy dose with minimal side effects on PB-MNCs
may also vary between patients. Monitoring the invasive
and migratory function of PB-MNCs may help determine
the optimal maximum radiation dosage for any given
patient. As an example of how ECIS may be a more sensi-
tive measurement of cell health and potential individual
susceptibility to radiation toxicity than a standard viability
assay, we show here that 24 hours after exposure of PB-
MNCS to either no radiation (control cells) or 2.15 Gy of
radiation the viability measurements for the two PB-MNC
populations were similar, but the ECIS invasion measure-
ments are significantly different for the nonirradiated PB-
MNCs versus those irradiated with 2.15 Gy. Other studies
have shown that radiation of mouse macrophages up to
2 Gy had no effect on cell viability using an Alamar Blue
metabolic conversion assay [71]. However, both the
Trypan blue and Alamar Blue dye assays have their
limits regarding sensitivity and accuracy in detecting
changes in cell viability, which could account for why
we found no differences in viability between the un-
treated and irradiated PB-MNCs [72–74]. It is also pos-
sible that the low-dose X-ray radiation of the PB-MNCs
could affect the cell signal transduction mechanisms
[75], or the ability of the cells to properly adhere to the
matrix coating on the filter [76], both of which could
affect the cells’ ability to transmigrate through the filter.
It should be noted that the effects of radiation on rat
PB-MNC migration have been reported using a conven-
tional Transwell assay [77], but again this manual
Transwell assay is laborious and time consuming, and
can only measure one experimental time point at the
end of several hours.
As discussed, studies have shown that a BM-MNC prod-
uct’s invasive functional capacity correlates to its myocar-
dial regenerative capacity, although the cell product’s
migratory and invasive function was assessed by standard
techniques making the results available only after the cell
product was delivered. ECIS measurement of BM-MNC
migration and invasion could make that information avail-
able as part of the cell product’s release criteria, potentially
preventing the invasive delivery of cells in instances where
they will not have regenerative efficacy. Future studies will
confirm the utility of the method described here for ECIS
Matrigel-coated Transwell invasion assays for assessing
BM-MNC product functional capacity and PB-MNC
function in association with disease and therapies.
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Conclusions
The ECIS Transwell filter system developed and tested
in this study was found to be rapid, accurate, and sensitive
for measuring the functional invasion activity of BM-
MNCs and PB-MNCs. Given the marked variability in
stem and progenitor cell functionality, especially in older
patients considered for autologous bone marrow stem and
progenitor regenerative medicine treatments, this assay
could be used to identify prospectively poorly functioning
harvested and prepared stem cells whose use in patients is
unlikely to result in significant benefit. Prospectively iden-
tifying functional stem cell preparations would reduce pa-
tient risks for procedures unlikely to provide clinical
benefit as well as decrease the numbers of patients needed
for clinical trials in regenerative medicine, This ECIS
Transwell filter system has the potential to be used as an
alternative diagnostic platform for any cell type where cell
migration or invasion is being studied in conventional
Boyden or Transwell filter assays using custom or com-
mercially available filters. Finally, this ECIS Transwell de-
vice could also supply robust, unambiguous, reproducible,
and cost-effective data as a potency assay for cell product
release and FDA regulatory strategies.
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